Marketing

Exaeris commences formal operations

Published in Gene Therapy Weekly, January 26th, 2006

Inyx, Inc., (IYXI), a specialty-pharmaceutical company with a focus on niche drug-delivery technologies and products, announced that its new, wholly owned sales and marketing subsidiary, Exaeris, Inc., has commenced formal operations.

"Exaeris is focusing on the direction and execution of commercial activities independent of Inyx's client manufacturing operations," said Jack Kachkar, MD, chairman & CEO of Inyx.

"Through Exaeris, we will build the necessary commercial resources to drive additional revenues and benefits to Inyx and our industry partners," Kachkar added.

Stephen Beckman, vice president sales & marketing and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2006-01-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry